Imperial College London
Portrait Picture

Professor Hashim Ahmed

Faculty of Medicine, Department of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bakavicius:2022:10.1590/S1677-5538.IBJU.2021.0091,
author = {Bakavicius, A and Marra, G and Macek, P and Robertson, C and Abreu, AL and George, AK and Malavaud, B and Coloby, P and Rischmann, P and Moschini, M and Rastinehad, AR and Sidana, A and Stabile, A and Tourinho-Barbosa, R and de, la Rosette J and Ahmed, H and Polascik, T and Cathelineau, X and Sanchez-Salas, R},
doi = {10.1590/S1677-5538.IBJU.2021.0091},
journal = {International Brazilian Journal of Urology},
pages = {263--274},
title = {Available evidence on HIFU for focal treatment of prostate cancer: a systematic review},
url = {http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.0091},
volume = {48},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Purpose: Prostate cancer (PCa) is the second most common oncologic disease amongmen. Radical treatment with curative intent provides good oncological results for PCasurvivors, although definitive therapy is associated with significant number of seriousside-effects. In modern-era of medicine tissue-sparing techniques, such as focal HIFU,have been proposed for PCa patients in order to provide cancer control equivalent tothe standard-of-care procedures while reducing morbidities and complications. Theaim of this systematic review was to summarise the available evidence about focalHIFU therapy as a primary treatment for localized PCa.Material and methods: We conducted a comprehensive literature review of focal HIFUtherapy in the MEDLINE database (PROSPERO: CRD42021235581). Articles published inthe English language between 2010 and 2020 with more than 50 patients were included.Results: Clinically significant in-field recurrence and out-of-field progression weredetected to 22% and 29% PCa patients, respectively. Higher ISUP grade group, morepositive cores at biopsy and bilateral disease were identified as the main risk factorsfor disease recurrence. The most common strategy for recurrence management wasdefinitive therapy. Six months after focal HIFU therapy 98% of patients were totallycontinent and 80% of patients retained sufficient erections for sexual intercourse.The majority of complications presented in the early postoperative period and wereclassified as low-grade.
AU  - Bakavicius,A
AU  - Marra,G
AU  - Macek,P
AU  - Robertson,C
AU  - Abreu,AL
AU  - George,AK
AU  - Malavaud,B
AU  - Coloby,P
AU  - Rischmann,P
AU  - Moschini,M
AU  - Rastinehad,AR
AU  - Sidana,A
AU  - Stabile,A
AU  - Tourinho-Barbosa,R
AU  - de,la Rosette J
AU  - Ahmed,H
AU  - Polascik,T
AU  - Cathelineau,X
AU  - Sanchez-Salas,R
DO  - 10.1590/S1677-5538.IBJU.2021.0091
EP  - 274
PY  - 2022///
SN  - 1677-5538
SP  - 263
TI  - Available evidence on HIFU for focal treatment of prostate cancer: a systematic review
T2  - International Brazilian Journal of Urology
UR  - http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.0091
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000765644900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.scielo.br/j/ibju/a/TfBygqLDznm4n9BV76MxttF/?lang=en
UR  - http://hdl.handle.net/10044/1/98234
VL  - 48
ER  -
Download